Baricitinib (Olumiant®) is indicated for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||14/12/2020|
|Rapid review completed||28/01/2021|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that baricitinib not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.